Double-blind crossover clinical pharmacology study comparing moxestrol (R 2858) and ethinyl estradiol in postmenopausal women.
The potency of 5 migrogram moxestrol (R 2858). 11beta-methoxy-17alpha-ethinyl-estra-1,3,5-[10]-triene-3,17-diol, administered orally, was compared to that of 25 microgram ethinyl estradiol in a double-blind crossover clinical pharmacology study of six postmenopausal women. At these doses, both compounds increased the eosinophilic index and decreased serum LH and FSH levels. A marked effect on circulating prolactin was observed only during ethinyl estradiol treatment.
D000368:Aged; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D004804:Eosinophils / Q000187:drug effects; D004997:Ethinyl Estradiol / Q000031:analogs & derivatives* / Q000494:pharmacology* / Q000627:therapeutic use; D005260:Female; D005640:Follicle Stimulating Hormone / Q000097:blood; D006801:Humans; D007986:Luteinizing Hormone / Q000097:blood; D008593:Menopause / Q000187:drug effects*; D008875:Middle Aged; D011388:Prolactin / Q000097:blood
D004997:Ethinyl Estradiol; C011310:moxestrol; D011388:Prolactin; D007986:Luteinizing Hormone; D005640:Follicle Stimulating Hormone